Company

Via Nova Therapeutics, Inc.

Via Nova Therapeutics develops treatments for acute and subacute viral infections.

About

Founded in 2020 and based in California, US, Via Nova Therapeutics develops treatments for respiratory viruses and other viral infections. Its programs target influenza viruses, adenoviruses, rhinoviruses and human polyomaviruses. Co-founders include Kelly Wong and virologist Don Ganem. In September 2021, the company raised USD 20 million in Series A funding led by Aditum Bio to advance preclinical antiviral programs licensed from Novartis.

2Funding rounds

2Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in